Grebow P E, Treitman J A
J Pharm Sci. 1981 Dec;70(12):1310-2. doi: 10.1002/jps.2600701205.
Four beagle dogs received both an oral and intravenous dose (1 mg/kg) of indapamide in a crossover design. The blood levels and urinary excretion of intact indapamide were measured, and the pharmacokinetic parameters of the drug were defined. The results indicate that indapamide is completely bioavailable after an oral dose and does not undergo first-pass metabolism. Excretion of unchanged drug from the kidney accounted for only a small percentage of the drug's clearance. While the dog is very similar to the human in its handling of indapamide, the dogs clears indapamide approximately twice as fast as humans.
四只比格犬采用交叉设计接受了口服和静脉注射剂量(1毫克/千克)的吲达帕胺。测量了完整吲达帕胺的血药浓度和尿排泄情况,并确定了该药物的药代动力学参数。结果表明,口服吲达帕胺后生物利用度完全,且不经历首过代谢。肾脏对未改变药物的排泄仅占药物清除率的一小部分。虽然犬类在处理吲达帕胺方面与人类非常相似,但犬类清除吲达帕胺的速度约为人类的两倍。